A one-time pop singer with mega-money star connections hatches a $100M plan to invest in ‘contrarian’ biotech ideas

Even back in the day as the singer for Chester French, a two-man indie pop group that sporadically flared into public sight with songs like “She Loves Everybody,” DA Wallach had a rep as someone who knew people. Or could get to know them.

People like billionaire Ron Burkle, who created a tech fund with Wallach called Inevitable Ventures. Or Sean “Diddy” Combs, who connected the budding entrepreneur with Burkle as Wallach became an early investor in and “singer-in-residence” for Spotify.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

ENDPOINTS CAREERS

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

view job offer post your job now

TRENDING NOW

A one-time pop singer with mega-money star connections hatches a $100M plan to invest in ‘contrarian’ biotech ideas

This article is for premium subscribers only

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force

A one-time pop singer with mega-mon­ey star con­nec­tions hatch­es a $100M plan to in­vest in ‘con­trar­i­an’ biotech ideas

This article is for premium subscribers only

more like this

Head of Regulated Labs Market Strategy

Benchling

San Francisco, CA, USA

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

A one-time pop singer with mega-money star connections hatches a $100M plan to invest in ‘contrarian’ biotech ideas

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force